Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


18.12.2017

1 Ann Intern Med
1 Blood
1 BMC Gastroenterol
1 Clin Infect Dis
2 Eur J Gastroenterol Hepatol
1 Gastroenterology
3 Hepatology
6 J Hepatol
1 J Med Virol
5 J Viral Hepat
3 Lancet Glob Health
2 PLoS One
1 Proc Natl Acad Sci U S A
2 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Intern Med

  1. GRAHAM CS
    Making Do With What We Have.
    Ann Intern Med. 2017;166:850-851.
    PubMed     Text format    


    Blood

  2. TUCCI FA, Kitanovski S, Johansson P, Klein-Hitpass L, et al
    Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus-infected individuals.
    Blood. 2017 Dec 14. pii: blood-2017-09-805762. doi: 10.1182/blood-2017-09-805762
    PubMed     Text format     Abstract available


    BMC Gastroenterol

  3. CHIEN NH, Huang YT, Wu CY, Chang CY, et al
    Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy.
    BMC Gastroenterol. 2017;17:154.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  4. RICKLES M, Rebeiro PF, Sizemore L, Juarez P, et al
    Tennessee's In-State Vulnerability Assessment for a 'Rapid Dissemination of HIV or HCV Infection' Event Utilizing Data about the Opioid Epidemic.
    Clin Infect Dis. 2017 Dec 7. pii: 4706246. doi: 10.1093/cid/cix1079.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  5. ALSEBAEY A, Elhelbawy M, Waked I
    Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease.
    Eur J Gastroenterol Hepatol. 2017 Dec 13. doi: 10.1097/MEG.0000000000001013.
    PubMed     Text format     Abstract available

  6. DE LEMOS-BONOTTO M, Valle-Tovo C, Costabeber AM, Mattos AA, et al
    A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment.
    Eur J Gastroenterol Hepatol. 2017 Dec 8. doi: 10.1097/MEG.0000000000001019.
    PubMed     Text format     Abstract available


    Gastroenterology

  7. CHOI YS, Jung MK, Lee J, Choi SJ, et al
    Tumor Necrosis Factor-producing T-regulatory Cells are Associated With Severe Liver Injury in Patients With Acute Hepatitis A.
    Gastroenterology. 2017 Dec 8. pii: S0016-5085(17)36685.
    PubMed     Text format     Abstract available


    Hepatology

  8. CHHATWAL J, Samur S, Bethea ED, Ayer T, et al
    Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29723.
    PubMed     Text format     Abstract available

  9. GARCIA-TSAO G
    Regression of HCV cirrhosis: Time will tell.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29720.
    PubMed     Text format    

  10. WANG S, Wang H, Ding WX
    Pyroptosis, a Novel Player for Alcoholic Hepatitis?
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29725.
    PubMed     Text format    


    J Hepatol

  11. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    PubMed     Text format    

  12. ELSHARKAWY A, Raziky ME, Akel WE, Saeed KE, et al
    Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32478.
    PubMed     Text format     Abstract available

  13. HEZODE C, Reau N, Svarovskaia ES, Doehle BP, et al
    Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32476.
    PubMed     Text format     Abstract available

  14. HELLARD M, Scott N, Sacks Davis R, Pedrana A, et al
    Achieving hepatitis C elimination in Europe - to treatment scale up and beyond.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32486.
    PubMed     Text format    

  15. SODERHOLM J, Millbourn C, Busch K, Kovamees J, et al
    Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32485.
    PubMed     Text format     Abstract available

  16. ASSELAH T, Hassanein T, Waked I, Mansouri A, et al
    Eliminating Hepatitis C within Low Income Countries - the need to cure Genotypes 4, 5, 6.
    J Hepatol. 2017 Dec 8. pii: S0168-8278(17)32482.
    PubMed     Text format     Abstract available


    J Med Virol

  17. MATHUR P, Emmanuel B, Sneller M, Zhang X, et al
    Recovery of Hepatitis C Specific T-cell Responses after Rituximab Therapy in Hepatitis C Mixed Cryoglobulinemic Vasculitis.
    J Med Virol. 2017 Dec 13. doi: 10.1002/jmv.25002.
    PubMed     Text format     Abstract available


    J Viral Hepat

  18. READ SA, Parnell G, Booth D, Douglas MW, et al
    The Antiviral Role of Zinc and Metallothioneins in Hepatitis C Infection.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12845.
    PubMed     Text format     Abstract available

  19. ERMAN A, Sathya A, Nam A, Bielecki JM, et al
    Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12846.
    PubMed     Text format     Abstract available

  20. LIU DP, Lu W, Zhang ZQ, Wang YB, et al
    Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B.
    J Viral Hepat. 2017 Dec 12. doi: 10.1111/jvh.12842.
    PubMed     Text format     Abstract available

  21. RODRIGUEZ DE SANTIAGO E, Velazquez Kennedy K, Garcia Gonzalez M, Gea Rodriguez F, et al
    HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12843.
    PubMed     Text format     Abstract available

  22. SIMMONS R, Ireland G, Irving W, Hickman M, et al
    Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12844.
    PubMed     Text format     Abstract available


    Lancet Glob Health

  23. STOCKDALE AJ, Beloukas A, Gerretti AM
    Epidemiological data for hepatitis D in Africa - Authors' reply.
    Lancet Glob Health. 2018;6:e34.
    PubMed     Text format    

  24. DEBES JD, Shah S
    Epidemiological data for hepatitis D in Africa.
    Lancet Glob Health. 2018;6:e32.
    PubMed     Text format    

  25. TUAILLON E, Kania D, Gordien E, Van de Perre P, et al
    Epidemiological data for hepatitis D in Africa.
    Lancet Glob Health. 2018;6:e33.
    PubMed     Text format    


    PLoS One

  26. SMITH JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, et al
    Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence.
    PLoS One. 2017;12:e0189255.
    PubMed     Text format     Abstract available

  27. COMSTOCK E, Kim CW, Murphy A, Emmanuel B, et al
    Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.
    PLoS One. 2017;12:e0188314.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A


  28. Correction for Giang et al., Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
    Proc Natl Acad Sci U S A. 2017 Dec 11. pii: 1720228115.
    PubMed     Text format    


    Vaccine

  29. RISSMANN M, Ulrich R, Schroder C, Hammerschmidt B, et al
    Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31197.
    PubMed     Text format     Abstract available

  30. HABER P, Moro PL, Ng C, Lewis PW, et al
    Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Vaccine. 2017 Dec 11. pii: S0264-410X(17)31722.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: